Thus, PIM kinases mediate resistance of GBM cells to TRAIL by a p62-dependent mechanism, suggesting that targeting PIM kinases in combination with TRAIL may represent new therapeutic strategies against GBM. The gene discussed is TNFSF10; the disease is glioblastoma.